Recombinant Human Fc epsilon RI alpha/FCER1a Protein (c-His)

Cat # Size Price Quantity
633401100 μg$300
633402500 μg$900

Product Details


ApplicationBioassay
FormatLyophilized from sterile PBS, pH7.4.
Expression HostHEK293
Target NameFceR1a, FceR1-a, high affinity IgE receptor, FCER1A, FceR1 alpha,High affinity immunoglobulin epsilon receptor subunit alpha
SpeciesHuman
accession numberP12319
SourcesA DNA sequence encoding the human FCER1A (P12319) (Met1-Gln205) was expressed with a C-terminus His tag.
Molecular WeightThe protein has a predicted MW of 47.8 KDa. Due to glycosylation, the protein migrates to 70-78 KDa based on Bis-Tris PAGE result.
Affinity TagC-His
Purity≥95% as determined by SDS-PAGE. ≥90% as determined by SEC-HPLC
Regulatory StatusRUO
Endotoxin level< 1.0 EU per μg protein
Protein ConcentrationLyophilized
Storage and HandlingSamples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Background Information


Human Fc epsilon RI alpha (FcεRIα), also known as FCER1A or the high-affinity IgE receptor alpha subunit, is a transmembrane glycoprotein that plays a central role in allergic immune responses. It is expressed primarily on mast cells and basophils, where it serves as the ligand-binding component of the high-affinity receptor for immunoglobulin E (IgE). FcεRIα helps initiate immune responses against allergens and contributes to the rapid release of inflammatory mediators.



FcεRIα is a type I transmembrane protein belonging to the immunoglobulin superfamily. Its extracellular region contains two immunoglobulin-like domains that form the high-affinity IgE-binding site, followed by a single transmembrane segment and a short cytoplasmic region. On mast cells and basophils, FcεRI typically forms a tetrameric complex consisting of one α subunit, one β subunit, and two disulfide-linked γ subunits. The α subunit binds IgE, while the β and γ subunits contribute to receptor expression and intracellular signal transduction.



The principal ligand of FcεRIα is the Fc region of IgE. When allergen-specific IgE binds to FcεRIα on the cell surface, subsequent allergen exposure can cross-link adjacent IgE–receptor complexes. This activates intracellular signaling pathways, leading to mast-cell and basophil degranulation and the release of histamine, leukotrienes, prostaglandins, and inflammatory cytokines. These mediators contribute to immediate hypersensitivity reactions and allergic inflammation.



Dysregulated FcεRI signaling is associated with allergic diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergies, and anaphylaxis. Because FcεRIα is essential for IgE-mediated activation, it represents a potential target for therapeutic intervention. Strategies under investigation include blocking IgE–FcεRI interactions, inhibiting receptor activation, and developing soluble FcεRIα proteins to sequester IgE. These approaches may help reduce allergic inflammation and provide new opportunities for treating IgE-mediated disorders.

Data Sheets


Recombinant Human Fc epsilon RI alpha/FCER1a Protein (c-His) TDS

Frequently Asked Questions


What are InnoCyto's Cytokines and Growth Factors?
These are recombinantly expressed signaling proteins, including interleukins, interferons, chemokines, and growth factors, that mediate cell communication, proliferation, differentiation, and immune activation. They are produced for use as research reagents to stimulate, modulate, or study cellular responses in vitro and in vivo.

What expression systems are these proteins produced in, and does it matter for my application?
Cytokines and growth factors may be produced in mammalian, insect, or E. coli expression systems depending on the protein, and the system affects properties like glycosylation, folding, and bioactivity. Non-glycosylated proteins from E. coli are often suitable for cell culture stimulation assays, while glycosylation-dependent proteins may require mammalian- or insect-expressed versions for full biological activity — check the product page for the expression system and recommended applications.

How is bioactivity measured and confirmed for each lot?
Bioactivity is typically confirmed using a functional cell-based assay (e.g., proliferation, differentiation, or reporter assay) relevant to the specific cytokine or growth factor, and is reported as an EC50/ED50 value or specific activity (units/mg) on the Certificate of Analysis. Always reference the lot-specific CoA rather than assuming activity is identical across lots or products.

Are these proteins carrier-free, and does that matter for my experiment?
Carrier-free formulations (without BSA or other stabilizing proteins) are available for applications where carrier protein could interfere with downstream analysis, such as certain in vivo studies or proteomic work, while carrier-containing formulations offer improved stability for routine cell culture use. Choose the format that matches your assay's sensitivity to background protein content.

Can these cytokines and growth factors be used for in vivo studies?
Mouse proteins may be used in vivo, but suitability depends on your endotoxin requirements for in vivo use. Endotoxin minimum threshholds vary by product and are indicated on the individual product page. Always confirm the endotoxin specification and formulation on the Certificate of Analysis before using a product in an in vivo setting.

Have a product or application question? Consult our FAQs or contact us.